JG
KERX

Jefferies Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Jefferies Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-26,300
Closed -$133K – 2741
2015
Q4 		$133K Hold
26,300
– – ﹤0.01% 2014
2015
Q3 		$93K Sell
26,300
-19,500
-43% -$131K ﹤0.01% 2045
2015
Q2 		$457K Buy
+45,800
New +$491K ﹤0.01% 1604
2014
Q1 		– Sell
-26,000
Closed -$337K – 2523
2013
Q4 		$337K Buy
+26,000
New +$311K ﹤0.01% 1328

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Jefferies Group's KERX Position: Q1 2018 in Review

Jefferies Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 74,000 shares — an estimated $344K sold.

Jefferies Group first reported a position in KERX in Q2 2013 and held it in 4 quarters. The position peaked at $344K in Q4 2017. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Jefferies Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Jefferies Group sold 74,000 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $344K.
  • Jefferies Group first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 4 quarters.
  • Jefferies Group's Keryx Biopharmaceuticals Inc position peaked at $344K in Q4 2017.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Jefferies Group's 13F filing for Q1 2018, filed 15 May 2018.